Novel signal transduction modulators for the treatment of airway diseases

被引:49
作者
Barnes, PJ [1 ]
机构
[1] Imperial Coll Sch Med, Natl Heart & Lung Inst, London SW3 6LY, England
关键词
inflammation; nuclear factor-kappa B; MAP kinase; Syk kinase; phosphoinositide-3; kinase;
D O I
10.1016/j.pharmthera.2005.08.001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Multiple signal transduction pathways are involved in the inflammatory process in the airways of patients with asthma and chronic obstructive pulmonary disease (COPD), hence modulators of these pathways may result in novel anti-inflammatory treatments. The advantage of this approach is that these pathways are activated in many inflammatory and structural cells of the airways, hence a broad spectrum of anti-inflammatory effects may be possible. However, this also makes it more likely that side effects may be limiting, but this may not be a problem if the signal transduction pathway is selectively activated in disease and the therapeutic index may be increased by inhaled delivery. Phosphodiesterase-4 (PDE4) inhibitors are the most advanced treatment in this category as anti-inflammatory treatment for asthma and COPD, although side effects are dose limiting. Other promising approaches are inhibitors of p38 mitogen-activated protein (MAP) kinase, inhibitor of nuclear factor-kappa B kinase-2 (IKK2), and Syk kinase, all of which are in clinical development. Several other kinases and transcription factors are also targets for novel drug development. It is likely that modulators of signal transduction pathways may lead to the development of several novel anti-inflammatory treatments for asthma and COPD in the future. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:238 / 245
页数:8
相关论文
共 82 条
[1]  
Adachi T, 1999, J IMMUNOL, V163, P939
[2]   Src family-selective tyrosine kinase inhibitor, PP1, inhibits both Fc epsilon RI- and Thy-1-mediated activation of rat basophilic leukemia cells [J].
Amoui, M ;
Draber, P ;
Draberova, L .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1997, 27 (08) :1881-1886
[3]  
[Anonymous], COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003562.PUB2
[4]   Effect of PDE4 inhibitors on zymosan-induced IL-8 release from human neutrophils: Synergism with prostanoids and salbutamol [J].
Au, BT ;
Teixeira, MM ;
Collins, PD ;
Williams, TJ .
BRITISH JOURNAL OF PHARMACOLOGY, 1998, 123 (06) :1260-1266
[5]   Mediators of chronic obstructive pulmonary disease [J].
Barnes, PJ .
PHARMACOLOGICAL REVIEWS, 2004, 56 (04) :515-548
[6]   New drugs for asthma [J].
Barnes, PJ .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (10) :831-844
[7]   Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase [J].
Barnes, PJ ;
Ito, K ;
Adcock, IM .
LANCET, 2004, 363 (9410) :731-733
[8]   Anti-leukotrienes: here to stay? [J].
Barnes, PJ .
CURRENT OPINION IN PHARMACOLOGY, 2003, 3 (03) :257-263
[9]   Prospects for new drugs for chronic obstructive pulmonary disease [J].
Barnes, PJ ;
Hansel, TT .
LANCET, 2004, 364 (9438) :985-996
[10]  
Barnes PJ, 1998, PHARMACOL REV, V50, P515